Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Allakos Inc ALLK

Healthcare Biotechnology
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ALLK)

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire March 14, 2024

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

GlobeNewswire February 26, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK

Accesswire February 13, 2024

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire February 12, 2024

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

GlobeNewswire February 12, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK

Newsfile February 9, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK

PR Newswire February 7, 2024

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire February 7, 2024

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire February 6, 2024
View More News ››

Opinion & Analysis (NDAQ:ALLK)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ALLK)

Allakos Presents Preclinical Data Highlighting Inhibition of

News; $ALLK Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024@...
whytestocks - February 26, 2024

SHOULD ALLAKOS INC BE ON YOUR INVESTMENT WATCHLIST?

$ALLK  Allakos Inc. (NASDAQ:ALLK), a clinical-stage biopharmaceutical company developing therapeutic monoclonal antibodies for...
AviseAnalytics - January 10, 2022
View more Bullboard ››

Coelacanth Energy Inc.

Coelacanth Energy Inc.

Coelacanth Energy Inc. is a Montney-focused oil and natural gas exploration and development company, with lands located in ...
View More »